AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 6246005
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (pivmecillinam and pivampicillin)
Trial: 28810061
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg IR CTC (equivalent to 88 mg tramadol and 112 mg celecoxib)
Trial: 28810061
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg IR tramadol
Trial: 28888220
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg celecoxib
Trial: 28810061
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg IR tramadol and 100 mg celecoxib
Trial: 25970619
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of AIMS and NSMDA
Trial: 19819790
Drug: Gabapentin 800
RxNorm normalized name: gabapentin 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabapentin 800 mg/daily for 30 days
Trial: 19819790
Drug: Diclofenac 75
RxNorm normalized name: CAPSAICIN 0.025%/DICLOFENAC 75MG KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac 75 mg/daily for 30 days
Trial: 9585270
Drug: Propofol IV
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol IV infusion titrated to electroencephalographic burst suppression during CPB
Trial: 9585270
Drug: Propofol IV
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol IV infusion
Trial: 7618427
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg pentazocine
Trial: 2729164
Drug: Pure beta-carotene
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pure beta-carotene (12 or 30 mg)
Trial: 2729164
Drug: Carrots (270
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carrots (270 g)
Trial: 2729164
Drug: Broccoli (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Broccoli (600 g)
Trial: 2729164
Drug: Tomato juice
RxNorm normalized name: TOMATO JUICE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tomato juice (180 g)
Trial: 665561
Drug: Egg formula
RxNorm normalized name: EGG
DrugBank: Egg (DB10529)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Egg formula diet with higher protein level (0.6 g/kg)
Trial: 665561
Drug: Rural Guatemalan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rural Guatemalan diet (0.0875 g protein/kg)
Trial: 24089589
Drug: Strength Training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Strength Training + Testosterone Treatment (ST + TT)
Trial: 2468628
Drug: Oral information
RxNorm normalized name: Inflammation OTC Bruise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral information
Trial: 15841789
Drug: Written and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Written and oral information
Trial: 9924533
Drug: Single infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single infusion of 5 mg/kg ABLC (Group A)
Trial: 9924533
Drug: Two infusions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two infusions of 5 mg/kg ABLC given 5 days apart (Group B)
Trial: 9924533
Drug: Two infusions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two infusions of 5 mg/kg ABLC on consecutive days (Group C)
Trial: 9924533
Drug: Higher dose
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher dose ABLC (10-15 mg/kg.day) for treatment failures
Trial: 9924533
Drug: Conventional amphotericin
RxNorm normalized name: amphotericin
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional amphotericin B (0.75-1.0 mg/kg on alternate days over 30-34 days)
Trial: 30306284
Drug: 100% oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100% oxygen at 7 L/min
Trial: 30306284
Drug: 100% oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100% oxygen at 12 L/min
Trial: 28073680
Drug: Simultaneous initiation
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Simultaneous initiation of Vitamin B12 and Folate supplementation (within 24 hours of chemotherapy initiation)
Trial: 26196407
Drug: ARB/TZ combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ARB/TZ combination therapy
Trial: 26196407
Drug: ARB/CCB combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ARB/CCB combination therapy
Trial: 17307706
Drug: SSRIs (sertraline,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SSRIs (sertraline, citalopram, paroxetine)
Trial: 17307706
Drug: GABAergic agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GABAergic agents (vigabatrin, tiagabine, topiramate, phenobarbitone)
Trial: 9681342
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human interferon gamma, 50 microg/m2, daily subcutaneous injection
Trial: 8595638
Drug: Cefuroxime axetil
RxNorm normalized name: Cefuroxime Axetil
DrugBank: Cefuroxime (DB01112)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefuroxime axetil 250 mg BID
Trial: 8595638
Drug: Amoxicillin/clavulanate 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin/clavulanate 500 mg TID
Trial: 322491
Drug: naproxen sodium
RxNorm normalized name: Naproxen Sodium
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: naproxen sodium (550 mg initial dose followed by 275 mg every six hours for a maximum of five days)
Trial: 25467017
Drug: Imetelstat (9.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imetelstat (9.4 mg/kg on days 1 and 8 of a 21-day cycle)
Trial: 21820095
Drug: Use of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of drug-eluting stents (DES) in patients with DM
Trial: 21820095
Drug: Use of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of drug-eluting stents (DES) in patients without DM
Trial: 17527093
Drug: Nucleoside-sparing regimen
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nucleoside-sparing regimen (lopinavir/ritonavir at 533/133 mg twice a day and efavirenz at 600 mg/d)
Trial: 15103923
Drug: Local anesthesia
RxNorm normalized name: Esters of benzoic acid for local anesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local anesthesia with 5-ml dose of 1% lidocaine injected into the periprostatic nerve plexus at 3 minutes before the procedure
Trial: 15103923
Drug: Local anesthesia
RxNorm normalized name: Esters of benzoic acid for local anesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local anesthesia with 5-ml dose of 1% lidocaine
Trial: 11473488
Drug: Exercise +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise + Hormone Replacement Therapy (ExHRT)
Trial: 9711449
Drug: Montelukast 5
RxNorm normalized name: montelukast 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Montelukast 5 mg/day
Trial: 3289850
Drug: Propionibacterium granulosum
RxNorm normalized name: Propionibacterium acnes
DrugBank: Propionibacterium acnes (DB19089)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propionibacterium granulosum KP-45 (10 mg infusion for at least 3 days before operation)
Trial: 21315003
Drug: Continuous blood
RxNorm normalized name: Dexcom G6 Receiver Continuous Blood-Glucose M
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous blood purification (CBP) with continuous veno-venous hemofiltration (CVVH) for 72 hours, ultrafiltrate volume 40 ml×kg(‐1)×h(‐1)
Trial: 21315003
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (routine treatment according to international guidelines)
Trial: 19720365
Drug: Live oral
RxNorm normalized name: Cholera Vaccine Live Oral
DrugBank: Vibrio cholerae CVD 103-HgR strain live antigen (DB14443)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live oral cholera vaccine 638 (2 x 10(9) CFU)
Trial: 15376518
Drug: 100-microA, 20-s
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100-microA, 20-s current pulses through saturated 20.4% NaCl solution
Trial: 11575110
Drug: GTR and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GTR and antibiotics (minocycline ointment locally, doxycycline and amoxyline systemically)
Trial: 30882524
Drug: Programmed intermittent
RxNorm normalized name: Program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Programmed intermittent epidural boluses (6-mL every 45 minutes with 0.1% ropivacaine and 2 microg/mL fentanyl)
Trial: 30882524
Drug: Continuous epidural
RxNorm normalized name: ACCU-BLOC PERIFIX CONTINUOUS EPIDURAL ANESTHESIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous epidural infusion (8 mL/h with 0.1% ropivacaine and 2 microg/mL fentanyl)
Trial: 31641199
Drug: Calibrated interdental
RxNorm normalized name: CALIBRATOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calibrated interdental brushes (IDBs) used daily on test sites.
Trial: 24717389
Drug: Usage of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usage of antidepressant medication
Trial: 7363436
Drug: Disopyramide (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Disopyramide (200 mg single dose)
Trial: 7363436
Drug: Propranolol (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (80 mg single dose)
Trial: 7363436
Drug: Chronic disopyramide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chronic disopyramide therapy (200 mg every 6 hours for 1 week)
Trial: 7363436
Drug: Chronic propranolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chronic propranolol therapy (80 mg every 8 hours for 1 week)
Trial: 7363436
Drug: Concurrent administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Concurrent administration of propranolol and disopyramide
Trial: 19136753
Drug: Butorphanol (1,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Butorphanol (1, 1.5 and 2 mg based on body weight)
Trial: 8719647
Drug: Placebo (intramuscular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (intramuscular saline)
Trial: 11464977
Drug: 60 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg/kg MSL-109
Trial: 11464977
Drug: 15 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg/kg MSL-109
Trial: 11464977
Drug: MSL-109 (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MSL-109 (60 mg and 15 mg combined) in D+/R- subgroup
Trial: 11464977
Drug: MSL-109 (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MSL-109 (60 mg and 15 mg combined) in D+/R+ and D-/R+ subgroup
Trial: 3661492
Drug: Cisplatin chemotherapy
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin chemotherapy (75‐100 mg/m2) and concomitant radiotherapy (20.00 Gy in 1 week) followed by full course (120 mg/m2 of cisplatin and 38.40 Gy of radiation)
Trial: 3661492
Drug: Full course
RxNorm normalized name: Full Marks
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full course (FC) therapy
Trial: 3661492
Drug: Partial course
RxNorm normalized name: rosin partially dimerized glycerol ester
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Partial course (PC) therapy
Trial: 31317668
Drug: Mepolizumab liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mepolizumab liquid formulation (100 mg) administered subcutaneously via prefilled syringe or autoinjector
Trial: 31317668
Drug: Lyophilized formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lyophilized formulation of Mepolizumab
Trial: 31317668
Drug: On-treatment adverse
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: On-treatment adverse events
Trial: 17269591
Drug: Contemporary treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contemporary treatment of gynecomastia
Trial: 10357727
Drug: 120 mg
RxNorm normalized name: papain 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120 mg orlistat 3 times daily
Trial: 7589634
Drug: hMG and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hMG and GH (any dose)
Trial: 30830077
Drug: Travoprost (0.004%)
RxNorm normalized name: Travoprost
DrugBank: Travoprost (DB00287)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Travoprost (0.004%) monotherapy
Trial: 25247485
Drug: High-dose dexamethasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose dexamethasone (HD-DXM) with low-dose dexamethasone maintenance (HD-DXM-M group)
Trial: 25247485
Drug: High-dose dexamethasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose dexamethasone (HD-DXM) without low-dose dexamethasone maintenance (HD-DXM-nM group)
Trial: 25247485
Drug: High-dose dexamethasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose dexamethasone with low-dose dexamethasone maintenance (HD-DXM-M group)
Trial: 19227171
Drug: Butorphanol 2
RxNorm normalized name: butorphanol 2 mg/mL injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Butorphanol 2 mg x day(‐1) + morphine 3.3 mg x day(‐1) (group MB)
Trial: 19227171
Drug: Morphine 3.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine 3.3 mg x day(‐1) alone (group M)
Trial: 19227171
Drug: Butorphanol 2
RxNorm normalized name: butorphanol 2 mg/mL injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Butorphanol 2 mg x day(‐1) alone (group B)
Trial: 16338599
Drug: Magnesium (450
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium (450 mg/day)
Trial: 11244702
Drug: Mivacurium (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mivacurium (0.2 mg.kg‐1) with non-invasive blood pressure measurement in the ipsilateral arm
Trial: 9286852
Drug: Mibefradil 100
RxNorm normalized name: mibefradil 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mibefradil 100 mg once daily for 3 weeks
Trial: 9286852
Drug: Mibefradil 100
RxNorm normalized name: mibefradil 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mibefradil 100 mg once daily
Trial: 9286852
Drug: Diltiazem SR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem SR 120 mg twice daily
Trial: 3553586
Drug: Diclofenac (75,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac (75, 100, or 125 mg/day)
Trial: 3553586
Drug: Indomethacin (75,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin (75, 100, or 125 mg/day)
Trial: 22615841
Drug: Individually tailored
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individually tailored guided self‐help treatment targeting depression and comorbid symptoms
Trial: 22615841
Drug: Standardized (non‐tailored)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardized (non‐tailored) Internet‐based treatment for depression
Trial: 15380292
Drug: Tiagabine (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiagabine (4 mg)
Trial: 15380292
Drug: Tiagabine (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiagabine (8 mg)
Trial: 17715212
Drug: Tiagabine (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiagabine (12 mg)
Trial: 17715212
Drug: Tiagabine (16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiagabine (16 mg)
Trial: 8851614
Drug: Oral fleroxacin;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral fleroxacin; single-dose trial; specific dosage not mentioned.
Trial: 1519232
Drug: Low molecular
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular weight heparin (5.000 anti XaU once daily)
Trial: 1519232
Drug: Standard heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard heparin (5.000 IU three times daily)
Trial: 6666231
Drug: ISDN treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ISDN treatment (240 mg daily, 6 X 40 mg)
Trial: 6666231
Drug: ISDN treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ISDN treatment
Trial: 26555148
Drug: NMES treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NMES treatment group (8-week daily NMES treatment)
Trial: 26555148
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (usual or conventional treatments)
Trial: 24789375
Drug: Atropine sulfate
RxNorm normalized name: Atropine Sulfate
DrugBank: Atropine (DB00572)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atropine sulfate eyedrops, 1% (1 drop daily)
Trial: 24789375
Drug: Both treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatments (Patching and Atropine)
Trial: 22078979
Drug: Irbesartan/hydrochlorothiazide (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irbesartan/hydrochlorothiazide (150 mg/12.5 mg day)
Trial: 22078979
Drug: Nebivolol/hydrochlorothiazide (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebivolol/hydrochlorothiazide (5 mg/12.5 mg day)
Trial: 19284181
Drug: Colloidal-Q10 (new
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colloidal-Q10 (new formulation)
Trial: 19284181
Drug: Oil-based formulation
RxNorm normalized name: phenylephrine hydrochloride / shark liver oil Rectal Cream [Formulation R]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oil-based formulation
Trial: 2294263
Drug: Papaverine (18
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Papaverine (18 mg)
Trial: 13094
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg iv chlorpheniramine
Trial: 13094
Drug: 5.5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5.5 mg/kg iv aminophylline
Trial: 13094
Drug: 8 mg
RxNorm normalized name: alloin 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg po chlorpheniramine
Trial: 13094
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg po butabarbital
Trial: 16847150
Drug: hsCRP 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hsCRP 1 to 3 mg/L
Trial: 27591455
Drug: Continuous epidural
RxNorm normalized name: ACCU-BLOC PERIFIX CONTINUOUS EPIDURAL ANESTHESIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous epidural infusion (Ropivacaine 0.15% plus Sufentanil 0.2μg/mL solution at 5mL/h)
Trial: 27591455
Drug: Programmed intermittent
RxNorm normalized name: Program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Programmed intermittent epidural bolus (Ropivacaine 0.1% plus Sufentanil 0.2μg/mL at 10mL/h)
Trial: 27591455
Drug: Programmed intermittent
RxNorm normalized name: Program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Programmed intermittent epidural bolus (Same solution as group A)
Trial: 27591455
Drug: Continuous epidural
RxNorm normalized name: ACCU-BLOC PERIFIX CONTINUOUS EPIDURAL ANESTHESIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous epidural infusion (Group A)
Trial: 22408272
Drug: Spinal mixture
RxNorm normalized name: brown mixture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spinal mixture of bupivacaine and morphine followed by oral oxycodone
Trial: 19597422
Drug: Plerixafor (0.24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plerixafor (0.24 mg/kg) and G-CSF (10 microg/kg for 4 days)
Trial: 16162699
Drug: Inhaled glucocorticoids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled glucocorticoids (fluticasone propionate, 1,000 microg/d) for 4 weeks
Trial: 11409425
Drug: Intravenous tissue
RxNorm normalized name: allogeneic processed thymus tissue Drug Implant [Rethymic]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous tissue plasminogen activator (t-PA) in patients with Apo E2 phenotype (27 patients)
Trial: 11409425
Drug: Intravenous tissue
RxNorm normalized name: allogeneic processed thymus tissue Drug Implant [Rethymic]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous tissue plasminogen activator (t-PA) in patients without Apo E2 phenotype (190 patients)
Trial: 3406540
Drug: Intravitreal infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravitreal infusion of thrombin
Trial: 2021881
Drug: Regular aqueous
RxNorm normalized name: Pen-Aqueous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular aqueous beclomethasone dipropionate (BDP) nasal spray (800 micrograms)
Trial: 2021881
Drug: As required
RxNorm normalized name: rabies vaccine, for intramuscular injection RETIRED CODE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: As required aqueous beclomethasone dipropionate (BDP) nasal spray (800 micrograms)
Trial: 329786
Drug: perphenazine, 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: perphenazine, 20 mg/day
Trial: 329786
Drug: amitriptyline, 125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: amitriptyline, 125 mg/day with perphenazine, 20 mg/day
Trial: 31601530
Drug: Housing First
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Housing First with assertive community treatment (HF-ACT)
Trial: 27699657
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (methotrexate 15 mg/day, sulfasalazine 1 g/day, and HCQ 400 mg/day)